** Shares of medical test kit maker Myriad Genetics MYGN.O fall ~3% to $13.27
** MYGN says it expects Q4 rev. to be between $209 mln and $211 mln, below analyst estimates of $212.9 mln - data compiled by LSEG
** Co expects Q4 adj. EPS to be between 3 cents and 4 cents vs. analyst est. of 3 cents
** Co forecasts 2025 rev. to be between $840 mln and $860 mln below analyst est. of $876.7 mln
** Co forecasts 2025 adj. EPS to be between 7 cents and 11 cents vs. analyst est. of 8 cents
** 6 of 16 brokerages rate the stock "buy" or higher, 6 "hold" and 4 "sell" or lower; their median PT is $20.50 - LSEG
** MYGN fell 27.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。